Actively Recruiting
Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2026-03-02
134
Participants Needed
1
Research Sites
122 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a multicenter, randomized, prospective Phase III study to evaluate the efficacy and safety of anlotinib plus whole-brain radiotherapy (WBRT) compared with WBRT alone in small cell lung cancer (SCLC) patients with brain metastases. Additionally, by investigating the association between changes in circulating tumor cell (CTC) levels in peripheral blood and treatment response to the combination of targeted therapy and radiotherapy, we aim to identify a patient subgroup most likely to benefit from this regimen, as well as potential biomarkers predictive of treatment efficacy.
CONDITIONS
Official Title
Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Small cell lung cancer confirmed by pathology with brain metastases diagnosed at initial presentation or during treatment, and measurable disease by RECIST criteria
- Expected survival time longer than 3 months
- Intracranial metastases count of 10 or fewer
- Adequate organ and bone marrow function
- Women of childbearing potential agree to use effective contraception during the study and for 6 months after completion
You will not qualify if you...
- Use of antiangiogenic drugs within the previous 1 month
- Non-small cell lung cancer including combined small cell carcinoma
- Small cell lung cancer with hilar invasion or hemoptysis
- Acute or subacute cerebral infarction or intracranial lesion hemorrhage
- Unresolved acute toxic reactions above grade 2 from prior treatments
- Advanced disease with severe symptoms, internal organ spread, or high risk of life-threatening complications
- Life-threatening severe or uncontrolled diseases
- Previous brain radiotherapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College
Beijing, Beijing Municipality, China, 100004
Actively Recruiting
Research Team
L
Lei Deng, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here